The recent surge in capital into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Stakeholder https://neiljvdo473617.idblogz.com/40503033/premium-investor-pharma-the-speculative-wager